http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
-
OpGen Strengthens Supplier Relationship to Use Industry-Leading Real-Time PCR Technology for New Acuitas® Tests
-
OpGen Introduces New RUO Rapid Test for Infection Control and Surveillance Studies
-
OpGen Acuitas® MDRO Gene Test Approved by NY State Department of Health
-
OpGen (OPGN) Reports Supply Agreement with Thermo Fisher Scientific (TMO) for Technology to Advance Acuitas Rapid Test
-
OpGen Signs Supply Agreement to Use Thermo Fisher Scientific’s Technology to Advance Acuitas® Rapid Test
-
OpGen’s Acuitas® Detection Technology Utilized in Publication Revealing Prevalence of CRE in Washington D.C. Healthcare Facilities
-
OpGen (OPGN) Says Data at ASM Microbe Demonstrates Potential of Acuitas Products
-
OpGen Data at ASM Microbe 2017 Demonstrates Potential of Acuitas Products for Predicting Antibiotic Susceptibility and Infection Control
-
OpGen to Receive Ignaz Semmelweis Award for Commitment to Combatting Infection Deaths
-
OpGen to Present Advancements in Antibiotic Susceptibility and Whole Genome Sequencing at ASM Microbe 2017
-
OpGen Appoints Tina S. Nova, Ph.D. to Board of Directors
-
OpGen Announces 2017 First Quarter Financial Results
-
OpGen Highlights Capabilities of its Acuitas® Technologies to Rapidly Predict Antibiotic Susceptibility Using Drug Resistance Gene Profiles at ECCMID
-
OpGen Announces Date of First Quarter 2017 Financial Results Conference Call
-
UPDATE -- OpGen to Present Antibiotic Resistance Prediction Data at 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
-
OpGen to Present Antibiotic Resistance Prediction Data at 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
-
Bioverativ Appoints Tim Harris Executive Vice President, Research and Development
-
OpGen Announces 2016 Fourth Quarter and Year End Financial Results
-
OpGen Announces Date of 2016 Fourth Quarter and Year End Financial Results Conference Call
-
OpGen to Present at the Cowen and Company 37th Annual Health Care Conference
-
OpGen (OPGN) Announces Prelim. Data Demonstrating Ability to Rapidly and Accurately Predict Bacterial Antibiotic Susceptibility with Gene Profiles
-
OpGen Presents Rapid Acuitas Genetic Test Data at Advances in Genome Biology and Technology Meeting
-
OpGen Reports Preliminary Fourth Quarter and Full Year 2016 Financial Results
-
OpGen Supports Passage of Landmark 21st Century Cures Act to Expedite Development of Solutions for Bacterial Infections
-
OpGen (OPGN) Issued 3.6M in Common Stock in ATM Offering
-
OpGen Provides ATM Program Update
-
OpGen (OPGN), Merck (MRK) Enter Rapid Diagnostics, IT Products Development Collaboration
-
OpGen Collaborates With Merck to Develop Novel Rapid Diagnostics and Informatics Tools to Combat Antibiotic Resistance
-
Large Integrated Health Outcomes Study Reveals Shifting Epidemiology In Drug Resistant Organisms
-
OpGen’s Infectious Disease Portfolio Highlighted at IDWeek 2016
-
OpGen Reports 2016 Third Quarter Financial Results and Provides Business Update
-
OpGen Announces Date of Third Quarter 2016 Financial Results Conference Call
-
OpGen to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
-
OpGen Reports 2016 Second Quarter Financial Results and Provides Business Update
-
OpGen, Inc. Announces Timing for Second Quarter Financial Results and Conference Call
-
OpGen Highlights Strong Performance of Acuitas® Resistome Test at ASM Microbe 2016
-
OpGen Announces Closing of $10 Million Private Placement
-
OpGen Supports New White House National Microbiome Initiative
-
OpGen Reports 2016 First Quarter Financial Results and Business Update
-
OpGen and District of Columbia Hospital Association Complete First Citywide Quantification of Multidrug-Resistant Organism (MDRO) Prevalence in Washington, D.C.-based Healthcare Facilities
-
OpGen Appoints Harry J. D'Andrea to Board of Directors
-
OpGen (OPGN) Announces Presentation of Positive QuickFISH Data at ECCMID
-
New Study Data Show OpGen’s QuickFISH® Blood Culture Pathogen ID Tests to be Rapid and Cost-Effective, with Utility to Inform Antimicrobial Stewardship Decisions
-
Fluidigm and OpGen Enter Into Strategic Agreement to Develop Multi-Drug Resistance Testing Kits and Equipment
-
Fluidigm and OpGen Enter into Strategic Agreement to Develop Multi-Drug Resistance Testing Kits and Equipment

